Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply
- PMID: 29852041
- DOI: 10.1001/jamaoncol.2018.0751
Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply
Comment on
-
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925. JAMA Oncol. 2018. PMID: 28975219 Free PMC article.
-
Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?JAMA Oncol. 2018 Jul 1;4(7):1017. doi: 10.1001/jamaoncol.2018.0745. JAMA Oncol. 2018. PMID: 29852042 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical